By Kashish Tandon and Rishika Sadam Jan 23 (Reuters) - Sun Pharmaceutical Industries, India's top drugmaker by revenue, said ...

India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE:OGN), a ...

Sun Pharmaceutical Industries Ltd. is talking with advisers about a possible bid for New York-listed wellness company Organon ...

Indian drugmakers Sun Pharmaceutical Industries , Zydus Lifesciences and Alkem Laboratories have received approval from India ...

Besides Sun Pharma, a growing roster of Indian drugmakers is lining up cheaper generic versions of semaglutide ahead of the ...

Jan 23 () - Sun ​Pharmaceutical ‌Industries, India's ‌top drugmaker by ⁠revenue, ‌said on Friday ‍that it has ​received ‌regulatory approval to manufacture and sell ⁠generic ​semaglutide ​in India.

Sun Pharma receives DCGI approval to launch generic semaglutide injection, Noveltreat, for weight management in India.

Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist Organon, after a report suggested ...

India's top drug maker Sun Pharmaceutical Industries has announced today the launch of a generic version of semaglutide, the main ingredient for Novo Nordisk's blockbuster weight-loss drug Wegovy and ...

Media reports this week suggested that Sun Pharma is in discussions with lenders to arrange financing for the acquisition and has submitted non-binding bids, which could value Organon at over $10 ...

Sun Pharma plans to launch by March and sell in five doses similar to the innovator Novo Nordisk’s drug Wegovy.

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market Semaglutide ...